# ECOG-ACRIN Cancer Research Group: Phase 2 study closed enrollment, 2175 enrolled (Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8)

**Score:** 55/100

| Field | Value |
|---|---|
| Sponsor | ECOG-ACRIN Cancer Research Group |
| Sponsor type | Research network |
| Study | CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy |
| NCT ID | NCT04266249 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Invasive Breast Carcinoma; Prognostic Stage II Breast Cancer AJCC v8 |
| Intervention types | drug, procedure, biological, radiation |
| Target enrollment | 2175 |
| Site countries | United States, Puerto Rico |
| Posted | 2020-02-12 |
| Planned start | 2020-03-13 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-19 |
| Last update posted | 2026-10-19 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 2175 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04266249). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.